Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol

Leukemia. 2024 Apr;38(4):912-913. doi: 10.1038/s41375-024-02201-1. Epub 2024 Mar 2.

Authors

Maria Agustina Perusini¹, Claire Andrews², Atenafu G Eshetu³, Vikas Gupta⁴, Dawn Maze⁴, Karen W L Yee⁴, Aniket Bankar⁴, Marta B Davidson⁴, Guillaume Richard-Carpentier⁴, Steven M Chan⁴, Aaron D Schimmer⁴, Jad Sibai⁵, Salman Alharbi⁴, Josephine A Lucero⁴, Swe Mar Linn⁴, Mark D Minden⁴, Andre C Schuh^#⁴, Hassan Sibai^#⁴

Affiliations

¹ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. agusperusini@gmail.com.
² Department of Haematology, St Vincent's University Hospital, Dublin, Ireland.
³ Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁴ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁵ University Health Network, Toronto, ON, Canada.

^# Contributed equally.

PMID: 38431747
DOI: 10.1038/s41375-024-02201-1

No abstract available

Publication types

Letter

MeSH terms

Adult
Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Asparaginase / therapeutic use
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Asparaginase
Antineoplastic Agents